To evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants.
Approach:
Study Design: A retrospective cohort study involving preterm infants admitted to the Neonatology Department of Inner Mongolia Maternity and Child Health Care Hospital.
Groups: Infants were divided into an immunization group receiving nirsevimab and a matched non-immunized group.
Data Collection: Clinical data, diagnostic and therapeutic processes were collected and analyzed.
Key Findings:
In the non-immunized group, twelve preterm infants (15.18%) developed RSV-associated respiratory infections, among whom 4 cases (5.06%) required non-invasive ventilator support, 2 cases (2.53%) experienced myocardial injury, 1 case (1.26%) had liver injury, 1 case (1.26%) experienced myocardial injury combined with liver injury, and 1 case (1.26%) exhibited wheezing symptoms.
Interpretation:
Limitations:
The study is limited to a single center and may not be generalizable to other populations.
The retrospective design may introduce biases in data collection and analysis.
Conclusion:
Nirsevimab may be effective in preventing RSV infections in preterm infants, warranting further research.
